Report Information More information from: https ://www.wis eguyreports .com/reports /495882
Humabs BioMed SA - Product Pipeline Review - 2016 Report / Search Code: WGR495882
Price
1-user P DF : $ 1500.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 3000.0
Enterprise P DF : $ 4500.0
Humabs BioMed SA - Product Pipeline Review - 2016 Summary Global Markets Direct’s , ‘Humabs BioMed SA - Product Pipeline Review - 2016’, provides an overview of the Humabs BioMed SA’s pharmaceutical res earch and development focus . The report provides comprehens ive information on the therapeutics under development by Humabs BioMed SA, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and the dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the pipeline therapeutic lands cape of Humabs BioMed SA - The report provides overview of Humabs BioMed SA including its bus ines s des cription, key facts , and locations and s ubs idiaries - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report as s es s es Humabs BioMed SA’s pipeline therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report features Humabs BioMed SA’s out-licens ed and partnered product portfolio and s ummarizes its dormant and dis continued projects Reas ons to buy - Evaluate Humabs BioMed SA’s s trategic pos ition with total acces s to detailed information on its product pipeline - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Humabs BioMed SA - Identify potential new clients or partners in the target demographic - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Humabs BioMed SA’s pipeline depth and focus of pipeline therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope
Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Humabs BioMed SA Snaps hot 6 Humabs BioMed SA Overview 6 Key Information 6 Key Facts 6 Humabs BioMed SA - Res earch and Development Overview 7 Key Therapeutic Areas 7 Humabs BioMed SA - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products /Combination Treatment Modalities 13 Pipeline Products - Out-Licens ed Products 14 Out-Licens ed Products /Combination Treatment Modalities 15 Humabs BioMed SA - Pipeline Products Glance 16 Humabs BioMed SA - Clinical Stage Pipeline Products 16 Phas e II Products /Combination Treatment Modalities 16 Phas e I Products /Combination Treatment Modalities 17 Humabs BioMed SA - Early Stage Pipeline Products 18 Preclinical Products /Combination Treatment Modalities 18 Dis covery Products /Combination Treatment Modalities 19 Humabs BioMed SA - Drug Profiles 20 Monoclonal Antibody for HCMV Infections 20 Product Des cription 20 Mechanis m of Action 20 R& D Progres s 20 FI-6 21 Product Des cription 21 Mechanis m of Action 21 R& D Progres s 21 mAb-100 22 Product Des cription 22 Mechanis m of Action 22 R& D Progres s 22 mAb-114 23 Product Des cription 23 Mechanis m of Action 23 R& D Progres s 23 Monoclonal Antibody for Dengue 24 Product Des cription 24 Mechanis m of Action 24 R& D Progres s 24 Monoclonal Antibody for HBV Infections 25 Product Des cription 25 Mechanis m of Action 25 R& D Progres s 25 Monoclonal Antibody for Influenza B Infections 26 Product Des cription 26 Mechanis m of Action 26 R& D Progres s 26 Monoclonal Antibody for Rabies 27 Product Des cription 27 Mechanis m of Action 27 R& D Progres s 27 Monoclonal Antibody for Staphylococcus Aureus Infections 28 Product Des cription 28 Mechanis m of Action 28 R& D Progres s 28 Monoclonal Antibody to Inhibit GM-CSF for Immunological Dis orders 29 Product Des cription 29 Mechanis m of Action 29 R& D Progres s 29 MPE-8 30 Product Des cription 30 Mechanis m of Action 30 R& D Progres s 30 NVB-71.4 31 Product Des cription 31 Mechanis m of Action 31 R& D Progres s 31 Monoclonal Antibody 1 for Undis clos ed Indication 32 Product Des cription 32 Mechanis m of Action 32
R& D Progres s 32 Monoclonal Antibody 2 for Undis clos ed Indication 33 Product Des cription 33 Mechanis m of Action 33 R& D Progres s 33 Monoclonal Antibody for Eps tein-Barr Viral Infection 34 Product Des cription 34 Mechanis m of Action 34 R& D Progres s 34 Monoclonal Antibody for Undis clos ed Indication 35 Product Des cription 35 Mechanis m of Action 35 R& D Progres s 35 Monoclonal Antibody for Viral Infections 36 Product Des cription 36 Mechanis m of Action 36 R& D Progres s 36 Monoclonal Antibody for Z ika Virus Infection 37 Product Des cription 37 Mechanis m of Action 37 R& D Progres s 37 Humabs BioMed SA - Pipeline Analys is 38 Humabs BioMed SA - Pipeline Products by Target 38 Humabs BioMed SA - Pipeline Products by Molecule Type 39 Humabs BioMed SA - Pipeline Products by Mechanis m of Action 40 Humabs BioMed SA - Dormant Projects 41 Humabs BioMed SA - Locations And Subs idiaries 42 Head Office 42 Appendix 43 Methodology 43 Coverage 43 Secondary Res earch 43 Primary Res earch 43 Expert Panel Validation 43 Contact Us 43 Dis claimer 44 Lis t of Tables Humabs BioMed SA, Key Information 6 Humabs BioMed SA, Key Facts 6 Humabs BioMed SA - Pipeline by Indication, 2016 8 Humabs BioMed SA - Pipeline by Stage of Development, 2016 10 Humabs BioMed SA - Monotherapy Products in Pipeline, 2016 11 Humabs BioMed SA - Partnered Products in Pipeline, 2016 12 Humabs BioMed SA - Partnered Products / Combination Treatment Modalities , 2016 13 Humabs BioMed SA - Out-Licens ed Products in Pipeline, 2016 14 Humabs BioMed SA - Out-Licens ed Products / Combination Treatment Modalities , 2016 15 Humabs BioMed SA - Phas e II, 2016 16 Humabs BioMed SA - Phas e I, 2016 17 Humabs BioMed SA - Preclinical, 2016 18 Humabs BioMed SA - Dis covery, 2016 19 Humabs BioMed SA - Pipeline by Target, 2016 38 Humabs BioMed SA - Pipeline by Molecule Type, 2016 39 Humabs BioMed SA - Pipeline Products by Mechanis m of Action, 2016 40 Humabs BioMed SA - Dormant Developmental Projects ,2016 41 Lis t of Figures Humabs BioMed SA - Pipeline by Top 10 Indication, 2016 8 Humabs BioMed SA - Pipeline by Stage of Development, 2016 10 Humabs BioMed SA - Monotherapy Products in Pipeline, 2016 11 Humabs BioMed SA - Pipeline by Target, 2016 38 Humabs BioMed SA - Pipeline by Molecule Type, 2016 39 Humabs BioMed SA - Pipeline Products by Mechanis m of Action, 2016 40
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349